Compared to non-proliferative HCCs, proliferative HCCs are typically more aggressive and less differentiated, (3, 5) and are frequently associated with higher serum α-fetoprotein (AFP) levels, TP53 mutations and poor outcome. HCCs previously profiled using gene expression microarrays, Désert et al. (7) report that non-proliferative HCCs are divided into two distinct subclasses, each preserving the periportal or perivenous phenotypes of the metabolic zonation that is critical for normal liver functioning.
To enable the prediction of CTNNB1 mutation status in the microarray metadata set, the investigators first defined a robust 5-gene signature using independent training and validation datasets with known CTNNB1 mutation status. The signature consists of three (GLUL, LRG5 and ODAM) and two (HAL and VNN1) genes whose expression positively and negatively, respectively, correlates with CTNNB1 mutation status. While GLUL and LRG5 are well-known Wnt target genes, the remaining three constitute novel HCC biomarkers.
Using HCC cell lines, the authors demonstrate that activating β-catenin signaling using GSK3β inhibitor 6-bromoindirubin-3′-oxime upregulates odontogenic ameloblast-associated protein (ODAM) and attenuates histidine ammonia lyase (HAL) and vanin 1 (VNN1) expression. Indeed, a network analysis of mouse liver periportal and perivenous signatures showed that, although ODAM, HAL and VNN1 were not present in the signatures, they were highly connected to the genes in the signatures. The 5-gene signature was found to have accuracies of 87% and 93% in the training and validation sets and was used to predict CTNNB1 mutations status for the meta-analysis.
The investigators report that hierarchical clustering of the 1,1113 HCCs revealed four subclasses with different prognoses. "ECM-type" (extracellular matrix) and "STEM-type" HCCs display signatures of high tumor cell proliferation and are associated with the S1/S2 (Wnt/TGF-β, poor prognosis) subclasses.(3) Additionally, the "ECM-type" subclass is characterized by signatures of ECM modelling, integrin signaling, epithelial-to-mesenchymal transition, while the "STEM-type" subclass is enriched for cancer stem cell, metastasis, cell cycle progression and p53 mutation signatures.
The remaining two subclasses display signatures of low proliferation and favorable prognosis and both show little intra-cluster variability. What is interesting, however, is that, gene set enrichment analyses revealed that these two classes reflect the tightly regulated metabolic zonation program of the liver (Figure 1 ). These two subclasses were named "perivenous-type" (PV) and "periportal-type" (PP) HCCs to reflect their resemblance to the phenotypes at the two ends of the metabolic zonation spectrum. The PV subclass is highly enriched for predicted CTNNB1 mutations and Wnt activation, the G6 subclass, The current study by Désert et al. (7) highlights the importance of interpreting HCC molecular classification in the context of basic liver biology and anatomy. Previous studies invariably identified a transcriptomically heterogeneous subset of well differentiated HCCs that display features consistent with or suggestive of hepatocytes. While some of these non-proliferative HCCs harbor CTNNB1 mutations and show β-catenin pathway activation, (1) (2) (3) 5) there is no agreement on the biological significance of the CTNNB1-wild-type subset. When viewed from the perspective of metabolic zonation, Désert et al. (7) demonstrate that nonproliferative HCCs recapitulate the phenotypes at the two distinct ends of the zonation program. In this context, the less aggressive clinical behavior of non-proliferative HCCs can be interpreted as their higher degree of preservation of normal liver phenotype. In particular, the lack of β-catenin activation in the PP-type HCCs would also be consistent with their least aggressive clinical and biological behavior. Notably, on the periportal vs perivenous spectrum, the only subclass that leans towards a perivenous phenotype is the PV-like, underscoring its unique biology compared to the other subclasses. Finally, the current study also provides a plausible explanation for the lack of prognostic difference between patients with CTNNB1-mutant or -wild-type HCCs,(10) as PV-type HCCs driven by β-catenin activation sit between proliferative HCCs and PP-type HCCs in terms of prognosis and highlights the molecular heterogeneity within the CTNNB1-wild-type subset. A more speculative interpretation of the current results raises the intriguing question of the cell of origin of HCCs. It remains to be seen whether the metabolic signatures observed in the various HCC subclasses merely reflect the metabolic programming along the porto-central axis or are indicative of their spatial origin.
A contextualized view of HCC molecular subclassifcation is crucial towards understanding HCC biology and identifying drug targets that consider the unique biology of liver cancer.
The study by Désert et al. (7) represents a significant step towards a unifying molecular classification of HCCs. Going forward, it will be of interest to validate the results from the current study on biopsy and resected HCC samples, aiming not only to obtain prognostic indicators but also to discover predictive biomarkers. 
